Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics.
Non-alcoholic fatty liver disease (NAFLD) is considered as the most common liver disease in Western countries with still rising prevalence due to a lifestyle favoring the development of the metabolic syndrome.


OBJECTIVE
To investigate the prevalence of ultrasound-diagnosed NAFLD in patients with referral for sonographic examination of the abdomen, and to determine risk factors.


METHODS
After exclusion of patients with known liver disease or risk factors for secondary NAFLD, a total of 155 arbitrarily selected patients (mean age 53.6±17.4 years; 52.6% male) from the interdisciplinary ultrasound department of a German University Hospital were included in this prospective study. Each patient underwent a standardized ultrasound, anthropometric and biochemical examination.


RESULTS
The prevalence of ultrasound-diagnosed NAFLD was 40.0%. NAFLD-patients had significantly higher body mass index (BMI) and waist-to-hip ratio, higher rates of reported hypertension and diabetes mellitus, and lower HDL cholesterol serum levels. Furthermore, NAFLD-patients revealed significantly higher serum ALT levels (23.2±22.1 U/l vs. 15.0±8.2 U/l; p=0.001), lower AST/ALT ratio (1.76±0.79 vs. 2.11±0.94; p=0.019), and notably, decreased flow in the portal vein (22.9±6.3 cm/s vs. 26.7±10.5 cm/s; p=0.011). Multivariate analysis revealed BMI (odds ratio (OR): 14.05; 95% Confidence interval (CI): 3.3-59.8), AST/ALT ratio (OR: 0.39; CI: 0.18-0.82), and HDL-C (OR: 4.33; CI: 1.6-11.9) as independent risk factors.


CONCLUSIONS
Ultrasound-diagnosed NAFLD is frequent in patients with referral for ultrasound examination of the abdomen, and our findings further support that NAFLD is the hepatic manifestation of the metabolic syndrome with obesity being the most important risk factor.
Kirovski
Georgi
G
Department of Internal Medicine I, University Hospital Regensburg Germany.
Schacherer
Doris
D
Wobser
Hella
H
Huber
Hanna
H
Niessen
Christoph
C
Beer
Catrin
C
Schölmerich
Jürgen
J
Hellerbrand
Claus
C
Obesity (Silver Spring). 2008 Jun;16(6):1394-9
18369343
Nat Med. 2005 Feb;11(2):183-90
15685173
Am J Gastroenterol. 1999 Apr;94(4):1018-22
10201476
Liver Int. 2006 Sep;26(7):856-63
16911469
Hepatology. 2001 Jul;34(1):121-5
11431742
Semin Liver Dis. 2001;21(1):17-26
11296693
J Clin Ultrasound. 2008 Mar-Apr;36(3):134-40
18196595
Am J Med. 1999 Nov;107(5):450-5
10569299
Enzyme. 1986;36(4):266-9
3569188
Mol Cell Biol. 2009 Aug;29(16):4527-38
19528226
World J Gastroenterol. 2007 Dec 21;13(47):6419-24
18081233
J Gastrointestin Liver Dis. 2009 Mar;18(1):61-6
19337636
J Gastroenterol Hepatol. 2008 Jun;23(6):829-32
18565017
Tohoku J Exp Med. 2008 May;215(1):89-93
18509239
J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10
16540768
Clin Gastroenterol Hepatol. 2006 Jun;4(6):797-801
16682255
J Hepatol. 2007 Jun;46(6):1126-32
17335930
Gut. 2003 Jan;52(1):126-9
12477773
Clin Gastroenterol Hepatol. 2006 Sep;4(9):1154-61
16904946
J Gastroenterol Hepatol. 2008 Jun;23(6):900-7
17995942
Hepatology. 2008 Sep;48(3):792-8
18752331
BMC Public Health. 2008 Aug 11;8:282
18694486
Hepatology. 2004 Dec;40(6):1387-95
15565570
J Korean Med Sci. 2008 Apr;23(2):256-61
18437009
J Gastroenterol Hepatol. 2007 Jun;22(6):788-93
17565631
J Gastroenterol Hepatol. 2009 Jul;24(7):1284-8
19476560
Hepatology. 2003 May;37(5):1202-19
12717402
Semin Liver Dis. 2004 Feb;24(1):3-20
15085483
J Hepatol. 2005 Sep;43(3):508-14
16006003
Hepatology. 2008 Aug;48(2):449-57
18627003
J Clin Gastroenterol. 2006 Sep;40(8):745-52
16940890
Hepatology. 2006 Dec;44(6):1564-71
17133468
Nat Med. 2005 Feb;11(2):191-8
15685170
Hepatology. 2005 Jul;42(1):44-52
15895401